Mr. Harold Wolkin reports

CYTOPHAGE APPOINTS NEW BOARD DIRECTOR

Michael D. Cochrane, a managing partner at Dixford Capital LLC, has joined the Cytophage Technologies Ltd. board of directors as its newest member. He will also join the audit and finance committee of the board. Mr. Cochrane's extensive experience as an investment banking veteran complements the board's wealth of expertise in research, product development, commercialization, finance and corporate governance.

Harold Wolkin, chairman of the Cytophage board, commented: "We are fortunate to attract a director of Michael's calibre to our board so early on after going public in February. Adding his expertise to our team contributes to our efforts to build an independent oversight body as Cytophage grows and evolves. His expertise in finance and the U.S. capital markets will be of great value as the company moves forward. On behalf of the Cytophage board, I warmly welcome Michael and look forward to working together."

About Mr. Cochrane

Mr. Cochrane is an investment banking veteran with more than 30 years of M&A (mergers and acquisitions) and finance experience in both New York and Toronto. During his 20-year career in New York, he held coverage and management positions at Goldman Sachs, Lehman Brothers, Credit Suisse and CIBC World Markets. Mr. Cochrane has specialized in M&A for growth companies focused on industry disruption through unique technologies, innovative business models or consolidation strategies.

Mr. Cochrane is currently the managing partner of Dixford Capital, an advisory and investment company that focuses on growing small and mid-sized business through implementing operational, financing and capital allocation strategies. Dixford is presently an investor in Lakeview Mortgage Funding, The Milbrook Corp., MCC Leasing, Aeris Communications and MacCosham Inc.

Previous positions include managing director in New York with UBS's Global Industrial Group, managing director with CIBC World Markets in Toronto and co-head of CIBC's global diversified industries investment banking group. Between 2014 and 2019, Mr. Cochrane taught M&A and economics courses in the MBA (master of business administration) programs at Queen's University's Smith School of Business and York University's Schulich School of Business.

With respect to this recent appointment, Mr. Cochrane said, "I am excited to work with the Cytophage directors and executives as they expand their commercialization efforts and grow their capital markets presence in Canada and the U.S."

About Cytophage Technologies Ltd.

Cytophage Technologies is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.